key: cord-1000247-xxr31519 authors: Sohrabi, Masoudreza; Rakhshankhah, Elham Sobhe; Ziaei, Hosein; Kachuee, Manizhe Ataee; zamani, Farhad title: Acute liver failure after vaccination against of COVID-19; a case report and review literature date: 2021-12-14 journal: Respir Med Case Rep DOI: 10.1016/j.rmcr.2021.101568 sha: a770575695e68aacedf92ddd18faaea8a0614ec8 doc_id: 1000247 cord_uid: xxr31519 BACKGROUND: Vaccination against COVID-19 remains as a main root of COVID-19 prevention. Few vaccines have been launched for this purpose recently with different side effects. Thrombotic events have been reported as a rare side effect after ChAdox1nCOV-19 vaccination that may cause death of recipient. CASE PRESENTATION: We report a case of hepatic artery occlusion after the first dose vaccination by ChAdOx1nCov-19.The patient was a health care worker, aged 34-year old. Past medical history was unremarkable and had not used heparin. Over the next couple of days after the vaccination, he reported headache, nausea, and dizziness as well as abdominal pain. His general status and the laboratories studies deteriorate quickly by increasing liver enzymes and severe coagulopathy. Clinically he had presented acute hepatic failure. He had been received blood products, prednisolone pulse along with broad antibiotics without benefit. He died on the sixth day. CONCLUSIONS: Thrombotic events after vaccination is very rare but can develop in main arteries with lethal outcome. This event may mimic autoimmune thrombosis clinically. Coronavirus disease 2019 (COVID-19) is a worldwide health problem according to recent world health organization more than 121 million confirmed cases and more A 34-years-old healthy man in mid may2021 came to local hospital due to refractory headache and myalgia one day after received his first dose of ChAdOx1nCov-19. Over next couple of days he reported abdominal pain with nausea and dizziness. The abdominal pain was resisted to pantoprazole and acetaminophen. His Past medical and familial history was unremarkable. As a health worker he checked regularly viral hepatitis as hepatitis Band C that were negative. He also had no history of regular medication or herbal medicines usage, alcoholic beverage of opium usage. Before vaccination COVID -19 was checked out by polymerase chain reaction (PCR) that was negative. He had hospitalized in local health center (at the fourth day after vaccination) but due to degrading of his situation, he transferred to our center as tertiary center and liver transplantation center. At admission (fifth day after vaccination) his blood pressure was 110/70mmHg, cardiac Pulse rate was 110 beat per second, respiratory rate reached to 30 per minute and temperature was 37ºC with Spo2 94%. The physical exam revealed moderate to severe abdominal pain on palpitation with the icteric sclera and petechial. The laboratory assessment at fifth day after vaccination in our center demonstrated the increasing of AST, ALT, bilirubin, D-dimer and elevated level of PT/INR (table 1) . A nasopharyngeal swab sample for SARS-CoV-2 reverse transcriptase polymerasechain-reaction (PCR) assay was negative. He underwent laboratory assessment for serology of other viral hepatitis such as hepatitis B and C, CMV, EBV also autoimmune hepatitis markers, ceruloplasmin level that all of them were negative. Complete Blood count (CBC ) with difference revealed significant elevation WBC level with low level platelet count, moreover prothrombin time(PT) and partial thrombin time (PTT) as well as C-reactive protein and D-dimer levels elevated ( table 1) . Also it is illustrated that almost all patients with vaccine induced thromboembolism thrombocytopenia syndrome has the antibody against PF4 without history of J o u r n a l P r e -p r o o f exposure to heparin. Activated platelets can be detected in serum of these patients (10, 11 The role of vaccines in which spike protein was used in liver of recipients is not clear. Furthermore, it is documented that adenovirus can bind to platelet and ultimately activated the platelet. This mechanism due to lack of enough copies of viruses may not work on the post vaccine thromboembolism thrombocytopenia (13) . Moreover, contraction between the virus spike protein with ACE protein in host cell may has a role in this manner as the virus spike protein binds ACE2 to gain cell entry (14) . Also other proteins such as trans membrane serine protease 2 (TMPRSS2) and paired basic amino acid cleaving enzyme (FURIN) are also important for infection (15) . There is few data regarding management of this event and it remain as a challenging issue .former studies illustrated the poor response to standard treatment of thrombosis but early treatment with intravenous immune globulin(IVIG), may provide good result against spontaneous heparin-induced thrombocytopenia((16). our finding have some clinically implications that VITT is a non-well known phenomena that usually affected young healthy subject and needs more COVID-19) dashboard SARS-CoV-2 vaccines in development Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial SARS-CoV-2 Vaccine-Induced Immune Thrombotic Thrombocytopenia. The New England journal of medicine Assessing a Rare and Serious Adverse Event Following Administration of the Ad26.COV2.S Vaccine Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. The New England journal of medicine Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination Is to the vaccine itself or to an autoimmune reaction to severe acute respiratory syndrome 2 coronavirus: insights and implications from previous reports in infected cases? New microbes and new infections Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination. The New England journal of medicine Autoimmune heparin-induced thrombocytopenia Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination COVID-19 and liver disease: mechanistic and clinical perspectives Domains and Functions of Spike Protein in Sars-Cov-2 in the Context of Vaccine Design TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells Use of intravenous immunoglobulin G to treat spontaneous heparin-induced thrombocytopenia High-dose intravenous immunoglobulin for the treatment and prevention of heparin-induced thrombocytopenia: a review. Expert review of hematology